Parallel Advisors LLC Sells 67 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Parallel Advisors LLC cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,165 shares of the medical research company’s stock after selling 67 shares during the quarter. Parallel Advisors LLC’s holdings in IQVIA were worth $1,801,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Smith Group Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at $1,616,000. Nordea Investment Management AB lifted its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. bought a new position in shares of IQVIA during the 4th quarter valued at $941,000. Fifth Third Bancorp lifted its holdings in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after buying an additional 1,521 shares during the period. Finally, Graphene Investments SAS lifted its holdings in shares of IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after buying an additional 2,700 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 1.9 %

Shares of NYSE:IQV opened at $188.45 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $256.34. The company has a 50-day moving average price of $196.06 and a 200 day moving average price of $209.52. The company has a market cap of $33.23 billion, a price-to-earnings ratio of 25.13, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Stifel Nicolaus reduced their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Bank of America cut their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.